when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

338 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT800 Endpoints604 BioPharma Dive231 onclive165 Fierce Biotech74 BioSpace70 raps29

therapy area

all Oncology81 Cardiology27 Psychiatry & CNS21 Vaccines17 Immunology17 Rare Disease12 Hepatology

Future Directions in Relapsed and Refractory Multiple Myeloma
onclive · 2mo ago↗ source
Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer
Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.
onclive · 2mo ago↗ source
Sequencing Strategies After Progression in Multiple Myeloma
onclive · 2mo ago↗ source

page 11 of 14

6

Infectious Disease4

EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy

In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung cancer.

onclive · 2mo ago↗ source

Sequencing ADCs in Endometrial Cancer

Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.

onclive · 2mo ago↗ source

Second Clinical Scenario - Progressive Disease Despite Hematocrit Control

Polycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.

onclive · 2mo ago↗ source

Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL

Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.

onclive · 2mo ago↗ source

Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma

Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.

onclive · 2mo ago↗ source

Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL

Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.

onclive · 2mo ago↗ source

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.

onclive · 2mo ago↗ source

INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC

First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.

onclive · 2mo ago↗ source

Treatment Intensification Gains Momentum in mCSPC Management

During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.

onclive · 2mo ago↗ source

FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations

Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.

onclive · 2mo ago↗ source

Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT

R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.

onclive · 2mo ago↗ source

Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection

In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma.

onclive · 2mo ago↗ source

Expanding ctDNA Applications to RCC and Germ Cell Tumors

Experts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.

onclive · 2mo ago↗ source

RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice

Learn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.

onclive · 2mo ago↗ source

ctDNA in Metastatic Urothelial Carcinoma

Experts explain how ctDNA tracking in metastatic cancer helps tailor immunotherapy, spot relapse early, and guide dose breaks—plus key limitations.

onclive · 2mo ago↗ source

Institutional Perspectives on Treatment Thresholds in PLGG

Experts weigh PLGG treatment choices, balancing chemo and MEK inhibitors, guided by vision decline, symptoms, tumor growth, and family logistics.

onclive · 2mo ago↗ source

Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups

In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians approach treatment selection in renal cell carcinoma across different IMDC…

onclive · 2mo ago↗ source

Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer

The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.

onclive · 2mo ago↗ source

Five Under 5: Top Oncology Videos for the Week of 5/3

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

onclive · 2mo ago↗ source

ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention

Judy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.

onclive · 2mo ago↗ source

The OncFive: Top Oncology Articles for the Week of 5/3

The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.

onclive · 2mo ago↗ source

Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT

R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.

onclive · 2mo ago↗ source